The identification and biochemical characterization of drug-like compounds that inhibit botulinum neurotoxin serotype A endopeptidase activity.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Toxicon

• Publication date

  2010-04-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.toxicon.2009.11.017PMID 20003913PMCID PMC2876331
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacophore-guided lead optimization: the rational design of a non-zinc coordinating, sub-micromolar inhibitor of the botulinum neurotoxin serotype a metalloprotease.

  2009cited by this paper
• Three‐Dimensional Database Mining Identifies a Unique Chemotype that Unites Structurally Diverse Botulinum Neurotoxin Serotype A Inhibitors in a Three‐Zone Pharmacophore

  2008cited by this paper
• A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate.

  2008cited by this paper
• How do the Botulinum Neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action

  2008cited by this paper
• Strategies to design inhibitors of Clostridium botulinum neurotoxins.

  2007cited by this paper
• Inhibition of Metalloprotease Botulinum Serotype A from a Pseudo-peptide Binding Mode to a Small Molecule That Is Active in Primary Neurons*

  2007cited by this paper
• A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease.

  2007cited by this paper
• Botulinum Neurotoxin Light Chain Refolds at Endosomal pH for its Translocation

  2006cited by this paper
• The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication.

  2006cited by this paper
• Identification of a botulinum neurotoxin A protease inhibitor displaying efficacy in a cellular model.

  2006cited by this paper
• Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting

  2006cited by this paper
• Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk.

  2005cited by this paper
• Conformational sampling of the botulinum neurotoxin serotype A light chain: implications for inhibitor binding.

  2005cited by this paper
• Enhancement of the endopeptidase activity of purified botulinum neurotoxins A and E by an isolated component of the native neurotoxin associated proteins.

  2004cited by this paper
• Identification of the major steps in botulinum toxin action.

  2004cited by this paper
• Presynaptic receptor arrays for clostridial neurotoxins.

  2004cited by this paper
• Substrate recognition strategy for botulinum neurotoxin serotype A

  2004cited by this paper
• Translocation of botulinum neurotoxin light chain protease through the heavy chain channel

  2003cited by this paper
• Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity.

  2003cited by this paper
• Microbiological, Biological, and Chemical Weapons of Warfare and Terrorism

  2002cited by this paper
• Biological and chemical agents: a brief synopsis.

  2002cited by this paper
• Tetanus and botulinum neurotoxins: turning bad guys into good by research.

  2001cited by this paper
• Botulinum toxin as a biological weapon: medical and public health management.

  2001cited by this paper
• High-throughput assays for botulinum neurotoxin proteolytic activity: serotypes A, B, D, and F.

  2001cited by this paper
• Intimate details of the most poisonous poison

  2000cited by this paper
• High-level expression, purification, and characterization of recombinant type A botulinum neurotoxin light chain.

  1999cited by this paper
• Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and dithiothreitol.

  1999cited by this paper
• A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

  1999cited by this paper
• Structure-Function Relationship of Clostridial Neurotoxins

  1999cited by this paper
• High-throughput screening

  1998cited by this paper
• Structure and function of tetanus and botulinum neurotoxins

  1995cited by this paper
• Tetanus and botulism neurotoxins: a new group of zinc proteases.

  1993cited by this paper
• How do tetanus and botulinum toxins bind to neuronal membranes

  1986cited by this paper
• A procedure for purifying neuron-like cells in cultures from central nervous tissue with a defined medium.

  1979cited by this paper

• Botulinum neurotoxin inhibitor binding dynamics and kinetics relevant for drug design.

  2021cites this paper
• Clostridial Neurotoxins: Structure, Function and Implications to Other Bacterial Toxins

  2021cites this paper
• TMT-based proteomics analysis to screen potential biomarkers of acute-phase TBI in rats.

  2020cites this paper
• Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin

  2018cites this paper
• The Mechanism of Inhibition of Botulinum Neurotoxin Type A by Two Quinolinol Compounds

  2017cites this paper
• A Novel Surface Plasmon Resonance Biosensor for the Rapid Detection of Botulinum Neurotoxins

  2017cites this paper
• Mechanism of inhibition of botulinum neurotoxin type A light chain by two quinolinol compounds.

  2017cites this paper
• High-Throughput Screening Uncovers Novel Botulinum Neurotoxin Inhibitor Chemotypes.

  2016cites this paper
• Selection of RNA Aptamers Against Botulinum Neurotoxin Type A Light Chain Through a Non-Radioactive Approach

  2016cites this paper
• Ex vivo inhibition of Clostridium botulinum neurotoxin types B, C, E, and F by small molecular weight inhibitors.

  2015cites this paper
• Recent developments with metalloprotease inhibitor class of drug candidates for botulinum neurotoxins.

  2015cites this paper
• Effect of botulinum neurotoxin type A (BoNTA) on the morphology and viability of 3T3 murine fibroblasts.

  2015cites this paper
• Challenges in Developing Biotoxin Inhibitors

  2015cites this paper
• High-throughput screening technologies for botulinum neurotoxins.

  2014cites this paper
• 8-Hydroxyquinoline and hydroxamic acid inhibitors of botulinum neurotoxin BoNT/A.

  2014cites this paper
• Current strategies for designing antidotes against botulinum neurotoxins

  2014cites this paper
• Cleavage of SNAP25 and Its Shorter Versions by the Protease Domain of Serotype A Botulinum Neurotoxin

  2014cites this paper
• Challenges in Developing Inhibitors Against Toxins

  2014cites this paper
• Paclitaxel is an inhibitor and its boron dipyrromethene derivative is a fluorescent recognition agent for botulinum neurotoxin subtype A.

  2013cites this paper
• Small-Molecule Quinolinol Inhibitor Identified Provides Protection against BoNT/A in Mice

  2012cites this paper
• High-throughput screening for modulators of protein-protein interactions: use of photonic crystal biosensors and complementary technologies.

  2011cites this paper
• High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.

  2011cites this paper
• Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors.

  2010cites this paper
• In vitro selection of RNA aptamers that inhibit the activity of type A botulinum neurotoxin.

  2010cites this paper
• Small Molecules Showing Significant Protection of Mice against Botulinum Neurotoxin Serotype A

  2010cites this paper